270 related articles for article (PubMed ID: 24829757)
1. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.
Ohno M; Ohkuri T; Kosaka A; Tanahashi K; June CH; Natsume A; Okada H
J Immunother Cancer; 2013; 1():21. PubMed ID: 24829757
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
4. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
[TBL] [Abstract][Full Text] [Related]
6. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
Chuntova P; Hou Y; Naka R; Yamamichi A; Chen T; Goretsky Y; Hatae R; Nejo T; Kohanbash G; Mende AL; Montoya M; Downey KM; Diebold D; Skinner J; Liang HE; Schwer B; Okada H
Neuro Oncol; 2022 Feb; 24(2):259-272. PubMed ID: 34347086
[TBL] [Abstract][Full Text] [Related]
7. High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms.
Thokala R; Binder ZA; Yin Y; Zhang L; Zhang JV; Zhang DY; Milone MC; Ming GL; Song H; O'Rourke DM
Front Oncol; 2021; 11():664236. PubMed ID: 34568006
[TBL] [Abstract][Full Text] [Related]
8. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Zhu H; You Y; Shen Z; Shi L
Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
10. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterisation of novel CAR-T cells to target IL13Rα2 positive human glioma in vitro and in vivo.
Leland P; Degheidy H; Lea A; Bauer SR; Puri RK; Joshi BH
Clin Transl Med; 2024 May; 14(5):e1664. PubMed ID: 38685487
[TBL] [Abstract][Full Text] [Related]
12. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
[TBL] [Abstract][Full Text] [Related]
13. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
[TBL] [Abstract][Full Text] [Related]
14. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH
PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266
[TBL] [Abstract][Full Text] [Related]
15. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
17. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
Shiina S; Ohno M; Ohka F; Kuramitsu S; Yamamichi A; Kato A; Motomura K; Tanahashi K; Yamamoto T; Watanabe R; Ito I; Senga T; Hamaguchi M; Wakabayashi T; Kaneko MK; Kato Y; Chandramohan V; Bigner DD; Natsume A
Cancer Immunol Res; 2016 Mar; 4(3):259-68. PubMed ID: 26822025
[TBL] [Abstract][Full Text] [Related]
19. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.
Goff SL; Morgan RA; Yang JC; Sherry RM; Robbins PF; Restifo NP; Feldman SA; Lu YC; Lu L; Zheng Z; Xi L; Epstein M; McIntyre LS; Malekzadeh P; Raffeld M; Fine HA; Rosenberg SA
J Immunother; 2019 May; 42(4):126-135. PubMed ID: 30882547
[TBL] [Abstract][Full Text] [Related]
20. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]